UNITY Biotechnology (UBX) Provides Pipeline and Business Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall St futures mixed ahead of CPI, bank earnings; US-Iran tensions in focus
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
UNITY Biotechnology Provides Pipeline and Business Updates
February 25, 2020 6:00 AM ESTPhase 2 study of UBX0101 in patients with osteoarthritis has completed enrollment
Topline 12- and 24-week results now expected in 2H 2020
First patient dosed in phase 1b study to explore higher dose and repeat doses
First-in-human study initiation for ophthalmology program expected in 2H 2020
SAN FRANCISCO, Feb. 25, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today provided... More
